CFS 1500 C for fast capsule filling

Published: 10-Feb-2010
Manufacturing Packaging Drug Delivery Pharmaceutical

An automated CFS 1500 C (containment) capsule filling and sealing system is now available from Capsugel, of Cambridge, UK, to provide rapid and safe filling and sealing of capsules containing lipid-based formulations or potent compounds for use in early phase clinical trials.

An automated CFS 1500 C (containment) capsule filling and sealing system is now available from Capsugel, of Cambridge, UK, to provide rapid and safe filling and sealing of capsules containing lipid-based formulations or potent compounds for use in early phase clinical trials.

The CFS 1500 C, which uses Capsugel's Licaps drug delivery technology, offers many of the timesaving benefits of the established CFS 1200. Additionally, it has accessible moving parts, which can be removed for manual or auto washer cleaning.

The CFS 1500 C has a throughput of 1,500 filled and sealed capsules per hour and is scalable to commercial manufacturing using the LEMS 70 liquid encapsulation micro-spray sealing system, which is capable of sealing up to 70,000 capsules per hour.

With the LEMS 70 and Licaps capsules, the CFS 1500 C can fill and seal capsules with a robust, impervious seal.

New software provides the CFS 1500 C with greater functionality and a weigh cell feature measures the weight of each filled capsule to ensure compliance with 21 CFR part 11.




  • Companies:
  • Lonza
See more

You may also like

Ingredients

De-risk early stage drug development with Lonza Advanced Synthesis

Read more
Located at stand 5.1B76, Lonza is set to shed light on the issues facing drug developers and how AI-assisted tools improve the process

Trending Articles

  1. Touchlight named most innovative new manufacturing facility at ISPE 2025 Facility of the Year Awards The company’s restored Victorian waterworks site in Hampton, London, has been recognised for transforming DNA manufacturing with its enzymatic, cell-free dbDNA platform
  2. Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
  3. Aseptic spray drying: Transforming biotherapeutics for a new era With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications
  4. ACG to invest $200m in US hard-shell capsule manufacturing ACG will build its first US capsule manufacturing facility in Atlanta, Georgia, with dedicated gelatine and HPMC lines, creating more than 200 jobs and expanding its North American presence ahead of operations starting in early 2027
  5. Takeda and Innovent Biologics partner to advance next-gen oncology medicines Takeda will establish manufacturing of two next-generation late-stage investigational medicines in the US and will receive exclusive commercialisation rights for IBI363 and IBI343 outside the US and China

You may also like

Ingredients

De-risk early stage drug development with Lonza Advanced Synthesis

Located at stand 5.1B76, Lonza is set to shed light on the issues facing drug developers and how AI-assisted tools improve the process
Manufacturing

Lonza receives Swissmedic approval for new high-potency biologics filling line in Stein

Lonza’s state-of-the-art aseptic filling line in Stein, Switzerland, has been granted GMP approval by Swissmedic, expanding the CDMO’s capacity for biologics and antibody-drug conjugates while strengthening its integrated, end-to-end manufacturing offering
Manufacturing

RION engages Lonza to scale manufacturing exosome based therapeutics

Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions
Manufacturing

Lonza publishes updated 2024 financials ahead of One Lonza reporting

New CDMO platform structure supports upcoming half-year 2025 results
Manufacturing

Lonza launches Design2Optimise platform to streamline API development

The Design2Optimise platform contributes to improved efficiencies and timelines to clinical trials of small molecule APIs
Manufacturing

Ethris and Lonza collaborate to develop spray-dried mRNA vaccines for respiratory disease prevention

Collaboration is part of Ethris’ strategy to develop spray-dried mucosal mRNA vaccines that are stable at room temperature and capable of generating a localised immune response, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), including a first candidate against influenza
Drug Delivery

Lonza and Ethris team up to develop mRNA vaccines for respiratory diseases

The two hope to produce a temperature-stable mRNA vaccine for influenza, which may promote mucosal immunity through its nasal delivery system
Subscribe now